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A B S T R A C T
Fusarium spp are rare but important opportunistic pathogens in immunocompromised patients.
Disseminated fusarial infections occur mostly in patients with hematologic malignancies with
myelosuppressive chemotherapy or in patients with severe immunodeﬁciency. Although more frequent
than Aspergillus fungemia, Fusarium fungemia remains a rare event. We describe the case of a female
patient with febrile neutropenia and persistent fungemia due to Fusarium solani, treated with
posaconazole and liposomal amphotericin B. A review of the literature for Fusarium spp fungemia was
carried out.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The incidence of invasive fungal infections is increasing and
Fusarium spp, a common soil mold, are among the emerging fungal
pathogens causing rare but important opportunistic infections in
immunocompromised patients.1,2 Members of the genus Fusarium
are halohyphomycetes belonging to the order Hypocreales
(ascomycetes). They are plant pathogens and soil saprophytes
that cause a broad spectrum of human infection,3,4 including
mycotoxicosis following ingestion of fusarial toxins, or tissue
invasion. In tissue, Fusarium hyphae resemble those of Aspergillus
and identiﬁcation may be difﬁcult. The taxonomy, biology, and
clinical aspects of Fusarium spp are well described by Nelson et al.3
Localized infections occur in both immunocompromised and
immunocompetent hosts. Disseminated fusarial infections occur
mostly in patients with hematologic malignancies with myelo-
suppressive chemotherapy or in patients with severe immunode-
ﬁciency. These can affect almost any organ and are deﬁned as the
involvement of two non-contiguous sites in association with more
than one positive blood culture.5,6 Fusarium species can be isolated
from cultures of blood samples in 40% of cases.4 Cases in which the
fungus has been recovered only from blood have been associated
with a better clinical outcome.7,8* Corresponding author. Tel.: +41 22 37 29 839; fax: +41 22 37 29 832.
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A 44-year-old white woman presented with a medical history
of multiple sclerosis since 2000, and invasive breast carcinoma
treated in 2007 with three cycles of ﬂuorouracil, epirubicin, and
cyclophosphamide chemotherapy (FEC), and three cycles of
taxotere chemotherapy, each cycle complicated by febrile neu-
tropenia.
Due to the diagnosis of an acute lymphoblastic leukemia (ALL)
type B in January 2008, the patient was hospitalized and
underwent leukocytapheresis and chemotherapy. She received
a prophylactic antimicrobial therapy with ﬂuconazole (200 mg
PO/day) and valaciclovir (500 mg PO/day), and imipenem
(4  500 mg IV/day) for fever suspected to have an infectious
origin. On day 4 after the beginning of chemotherapy, the patient
was still febrile. Between days 4 and 14, the patient became
agranulocytic and presented diarrhea caused by Clostridium
difﬁcile, which was followed by a bacteremia caused by
Enterococcus faecium.
On day 17, the patient was on treatment with ﬂuconazole
(200 mg PO/day), valaciclovir (500 mg PO/day), imipenem
(4  500 mg IV/day), metronidazole (3  500 mg PO/day) for the
treatment of diarrhea, and vancomycin (2  750 mg IV/day) and
gentamicin (3  80 mg IV/day) for the treatment of bacteremia. At
this time, a cutaneous erythematous lesion appeared on the ﬁrst
toe. Direct observation of the skin biopsy and blood revealed no
pathogen.ses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Cutaneous lesions caused by Fusarium solani.
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and the appearance of other cutaneous lesions, which thereafter
turned necrotic in the center (Figure 1). Fluconazole, gentamicin,
imipenem, and metronidazole were stopped, and treatment was
completed with amikacin (1 g IV/day), meropenem (3  1 g IV/
day), vancomycin (4  125 mg PO/day), and voriconazole
(2  300 mg IV/day) for suspicion of an invasive fungal infection.
To enlarge the antifungal spectrum, voriconazole was ﬁnally
stopped at the end of day 22 and replaced with posaconazole
(2  400 mg PO/day) and liposomal amphotericin B (5 mg/kg/day
IV). Direct observation on blood samples performed between days
22 and 26 revealed neither bacteria nor fungi. However,
ﬁlamentous fungi were observed in conjunctival secretions on
day 25. At this time, an abdominal computed tomography scan also
revealed hypodense splenic lesions considered to be related to
fungal emboli. Within the next few days, the general state of the
patient decreased dramatically, agranulocytosis was always
persistent, C-reactive protein increased up to 364 mg/l, and she
died 16 days after the appearance of the ﬁrst cutaneous lesion.
Blood cultures were performed daily from days 22 to 32. The
ﬁrst positive blood culture for Fusarium spp was recovered on day
27 and all following samples were also positive. Growth detection,
identiﬁcation, and the fungigram of the pathogenic organism,
Fusarium solani, were achieved only after the patient’s death.
3. Discussion
The widespread prophylactic use of ﬂuconazole has led to a
decline in Candida infections.9,10 However, the subsequent
changes in Candida epidemiology have resulted in the emergence
of other less susceptible fungal pathogens. In addition to
aspergillosis, infections caused by other molds have increased in
immunocompromised patients. Fusarium, Scedosporium, and
zygomycetes are examples of these pathogens. Fusarium infections
remain rare, but tend to be disseminated, and the prognosis is poor
as these fungi are resistant to many available antifungal agents.
The skin is often the initial clue to diagnosis, as cutaneous
lesions are observed in approximately 85% of patients with
disseminated Fusarium infections and often occur at an early stage
of the disease.5,6,11 While fusariosis in solid organ transplant
recipients is very rare with a lower incidence than zygomycosis
(<1–9%),12 it is more frequent in neutropenic cancer patients.13
Fusarium spp are emerging as pathogens that can cause serious
opportunistic infections in patientswith bonemarrow suppression
and neutropenia.6,14,15 They have also been reported to cause 15%
of invasive fungal infections occurring in patients with hemato-
logic malignancies.16
Themortality rate among patients with disseminated Fusarium
infection (75%) is twice as high as among patients with localinfection.2 Disseminated Fusarium infection carries a poor prog-
nosis, which is related to the angiotropism of Fusarium and its
capacity for adventitious sporulation in tissues,17 as well as the
underlying disease, the presence of neutropenia (<500 cells/l), and
late diagnosis and treatment. Recovery is furthermore very
difﬁcult if neutropenia persists.14,18
Fusarium species are relatively resistant to treatment with
antifungal agents. In vitro, amphotericin B is the most effective of
the antifungal agents. Fluconazole, itraconazole, and ﬂucytosine
have no activity against Fusarium species, and ketoconazole,
miconazole, terbinaﬁne, and echinocandins have limited activ-
ity.19–22 F. solani, in particular, is intrinsically resistant to
echinocandins.23 Amphotericin B is the agent of choice, but high
doses are required and may increase side effects. The liposomal
formulations are less toxic, but costly. The new triazole agents
(voriconazole, posaconazole, and ravuconazole) exhibit activity
against these fungi24 and are used for the treatment of fusariosis.
Voriconazole has been reported as a successful treatment for
disseminated fusariosis in patients with hemato-oncologic malig-
nancies25 or refractory fungal infections.26 It has also been used
successfully for the treatment of Fusarium peritonitis concomitant
to kidney transplantation.1
Nucci and Anaissie2 reported 12 Fusarium species associated
with infections. The most frequent species causing infections in
humans are F. solani, F. oxysporum, and F. moniliforme.3,7 A reported
case of F. sacchari fungemia in an immunosuppressed patient
shows that the pattern of infection, as well as the prognosis, may
vary according to the species involved.27 After renal transplanta-
tion, the patient presented a prolonged Fusarium fungemia from
postoperative days 11 to 24. He had no central venous catheter,
was clinically well, and had no skin lesions or other complaints
during infection. A small dose of amphotericin B (0.5 mg/kg daily)
was sufﬁcient to render blood cultures negative. The patient was
discharged after administration of a cumulative dose of 500 mg.27
Our patient described in the present report developed a
disseminated F. solani infection after receiving ﬂuconazole,
valaciclovir, imipenem, metronidazole, vancomycin, and genta-
micin. She received an empiric treatment with posaconazole and
liposomal amphotericin B. However, after a persistent fungemia,
the patient died while microbiological cultures were pending. The
fungigram revealed that the pathogenic agent, F. solani, was
resistant to ﬂuconazole, itraconazole, and ﬂucytosine, presented an
intermediate resistance to amphotericin B and ketoconazole, and
was sensitive to voriconazole and posaconazole.
This case highlights the poor outcome of an invasive fungal
disease caused by one of themost frequent Fusarium species. It also
provides evidence of the importance of the delay necessary to
typify the pathogenic fungi and the need to start empiric treatment
at the earliest stages of the infection. Fungemia was prolonged and
persistent in the ﬁnal stage of the disease in this patient.
The association of antifungal drugs plays also an important role
when Fusarium infection is suspected. New drugs, particularly the
new triazoles, may have a role in the treatment and prophylaxis of
Fusarium infections, but available data remain scarce. At present,
treatments with voriconazole (IV) + amphotericin B (IV) or
posaconazole (PO) + amphotericin B (IV) are the two main
alternatives. As mentioned, amphotericin B is the most active
agent against this fungus but, in this case, new azoles were more
active. In addition to antifungal treatment, strategies to improve
the host defenses and surgical intervention to remove necrotic
tissue are important measures that may improve the prognosis of
these infections.
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